The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Cholinergic dysfunction is one of the cornerstones of Alzheimer's disease (AD) pathology. Reviewed here is evidence evaluating relationships between smoking, nicotine exposure, nicotinic cholinergic signaling, and AD. Epidemiological studies initially indicating a lower incidence of AD in smokers now suggest conflicting results. Clinicopathological findings also are mixed as to how smoking behavior affects manifestation of AD markers. Studies that show nicotine-induced increases in nicotinic acetylcholine receptors (nAChR) and protection against age-related nAChR decline contrast, perhaps in a functionally relevant way, to losses of nAChR in AD. Although epidemiological, clinicopathological, and functional studies in humans do not present a cohesive picture, much in vitro data suggests neuroprotective properties of nicotine when used in models of neurodegenerative disorders. Studies of nicotine and nicotinic agonist effects on cognitive function in the non-demented and in AD are not compelling. More work is needed to ascertain whether acute or repetitive activation of nAChR with acute or intermittent exposure to nicotine or the persistent inactivation of nAChR with chronic nicotine exposure is a therapeutic objective and/or explains any pro-cognitive effects of those drugs. Other studies show complex interactions between nAChR, nicotinic agonists, and agents implicated in AD etiology. Thus, while controversies still exist, ongoing research is illuminating how nicotinic receptor changes and functions may be relevant to clinical, pathological and neurochemical changes that occur in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Dineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462 · cited 1×
“eral recent studies find evidence of interactions between β-amyloid and different nAChR subtypes, and some of these interactions affect nAChR function [16, 44,70,102].”
BackgroundPeng, X., Gerzanich, V, Anand, R., Whiting, P. J., & Lindstrom, J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09730-5 · Cited by 391
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163 · cited 1×
“A pilot trial on 6 AD patients administered ABT418 demonstrated improvement on recall tasks, spatial learning, and memory [71].”
Ke, L., Eisenhour, C. M., Bencherif, M., & Lukas, R. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37658-x · Cited by 136
Self-citationWang, H.-X., Fratiglioni, L., Frisoni, G. B., Viitanen, M., & Winblad, B. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009864 · Cited by 110
Rogers, S. W., Gahring, L. C., Collins, A. C., & Marks, M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-13-04825.1998 · Cited by 91
Reitstetter, R., Lukas, R. J., & Gruener, R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38184-4 · Cited by 87 · cited 1×
“This process is distinct from the more reversible process classically described as nAChR “desensitization” [10, 29,75].”
Self-citationWhitehouse, P. J., & Kalaria, R. N. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00002 · Cited by 79
Desensitization of Nicotine‐Stimulated 86Rb+ Efflux from Mouse Brain Synaptosomes
Marks, M. J., Grady, S. R., Yang, J., Lippiello, P. M., & Collins, A. C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63062125.x · Cited by 61
Cited by
The Effects of Tobacco Smoke and Nicotine on Cognition and the Brain
Swan, G. E., & Lessov-Schlaggar, C. N. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9035-9 · Cited by 580
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211
Repetitive transcranial magnetic stimulation and drug addiction
Barr, M. S., Farzan, F., Wing, V. C., George, T. P., Fitzgerald, P. B., & Daskalakis, Z. J. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.618827 · Cited by 78
“Unlike most neurotransmitter receptors, nAChRs are up-regulated in both animals and humans from chronic nicotine exposure (Wonnacott, 1990), thereby increasing the number of nicotine receptors (Benwell et al., 1988; Sabbagh et al., 2002).”
BackgroundSabbagh, M. N., Shah, F., Reid, R. T., Sue, L., Connor, D. J., Peterson, L. K. N., & Beach, T. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1771 · Cited by 57
Self-citation
Metadata
- Authors
- Sabbagh, M. N., Lukas, R. J., Sparks, D. L., & Reid, R. T.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2002-09-25
- Volume
- 4
- Issue
- 4
- Pages
- 317-325
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1507821648
- Cited by
- 57
- References
- 12
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.